THY1 and ovarian endometrioid adenocarcinoma: Overall survival was excellent in women with endometrioid ovarian cancers and at a clinical follow-up time of 5 years, neither cohort had reached > 25% mortality events, and there were no significant differences in overall survival by Thy-1 expression (Fig. 3d).